Acute exacerbation of carpal tunnel syndrome after Radiesse® injection for hand rejuvenation.
- Author(s): Feig, JL
- Ho, AM
- Isseroff, RR
- et al.
Published Web Locationhttps://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.17132
A calcium hydroxyapatite filler (CaHA, Radiesse® ; Merz Aesthetics, Franksville, WI, USA) became the first FDA-approved injectable filler for volume loss correction of the dorsal hands during rejuvenation.1 Within three months, the filler is processed by macrophage phagocytosis, and CaHA stimulates neocollagenesis for sustained results. The material does not stimulate calcifications or foreign body reactions, and allergy testing is not required. In fact, its chemically inert behavior contributes to its high degree of biocompatibility and favorable safety profile. Marmur et al. reported no long-term adverse events at 6 month follow-up. This article is protected by copyright. All rights reserved.